Cell

Adverum Biotechnologies will participate in the Jefferies Cell and Genetic Medicine Summit

Adverum Biotechnologies will participate in the Jefferies Cell and Genetic Medicine Summit

Adverum Biotechnologies, Inc. REDWOOD CITY, Calif., Sept. Feb. 23, 2022 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to make gene therapy a new standard of care for critical eye diseases. widespread, today announced that Peter Soparkar, Chief Operating Officer of Adverum Biotechnologies, will present at the Jefferies Cell and …

Adverum Biotechnologies will participate in the Jefferies Cell and Genetic Medicine Summit Read More »

Wugen will present at the upcoming Jefferies Cell & Genetic Medicine Summit

Wugen will present at the upcoming Jefferies Cell & Genetic Medicine Summit

ST. LOUIS & SAN DIEGO–(BUSINESS WIRE)–Wugen, Inc., a clinical-stage biotechnology company developing a portfolio of allogeneic cell therapies to treat a wide range of hematological and solid malignancies, today announced that management will participate in a fireside chat at 1:30 p.m. ET on Friday, September 30, 2022 at the upcoming Jefferies Cell & Genetic Medicine …

Wugen will present at the upcoming Jefferies Cell & Genetic Medicine Summit Read More »

ReCode Therapeutics to present at Jefferies Cell and Genetic Medicine Summit

ReCode Therapeutics to present at Jefferies Cell and Genetic Medicine Summit

MENLO PARK, Calif. & DALLAS, September 22, 2022–(BUSINESS WIRE)–ReCode Therapeutics, a genetic drug company using superior delivery to power the next wave of mRNA and gene correction therapies, today announced that David Lockhart, Ph.D, President and Chief Scientific Officer of ReCode Therapeutics, will provide an overview of the company at 8:00 a.m. ET on Thursday, …

ReCode Therapeutics to present at Jefferies Cell and Genetic Medicine Summit Read More »

Design Therapeutics to Present at Jefferies Cell and Genetic Medicine Summit 2022

Design Therapeutics to Present at Jefferies Cell and Genetic Medicine Summit 2022

Design Therapeutics, Inc. CARLSBAD, Calif., Sept. Feb. 22, 2022 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, announced today that João Siffert, MD, President and CEO, and Sean Jeffries, Ph.D., Chief Operating Officer, will participate in a fireside chat during the Jefferies Cell and …

Design Therapeutics to Present at Jefferies Cell and Genetic Medicine Summit 2022 Read More »

Center for Breakthrough Medicines signs agreement to manufacture jCyte's retinal degenerative disease cell therapy

Center for Breakthrough Medicines signs agreement to manufacture jCyte’s retinal degenerative disease cell therapy

jCell is a regenerative cell therapy for retinitis pigmentosa (RP) and other retinal degenerative diseases, which has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. Under the terms of the agreement, CBM will provide supplies for Phase 3 clinical trials and a commercial drug upon approval of the Biological License Application (BLA) of …

Center for Breakthrough Medicines signs agreement to manufacture jCyte’s retinal degenerative disease cell therapy Read More »

Instil Bio will present at the Jefferies Cell and Genetic Medicine Summit

Instil Bio will present at the Jefferies Cell and Genetic Medicine Summit

DALLAS, Sept. Feb. 19, 2022 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor-infiltrating lymphocyte, or TIL, therapies for the treatment of cancer patients, today announced that company management will participate in an upcoming investor conference: Jefferies Summit on Cells and Genetic MedicineCompany Overview and Q&A: Thursday, …

Instil Bio will present at the Jefferies Cell and Genetic Medicine Summit Read More »